Juan Mu
6PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Apr 23, 2024
Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.Jingyi Li, Juan Mu, Jia Wang
|Feb 23, 2022
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.Juan Mu, Haobin Deng, Cuicui Lyu
|May 01, 2021
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.Meijing Liu, Haobin Deng, Juan Mu
|Nov 18, 2020
Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.Qing Li, Juan Mu, Jijun Yuan
|Sep 03, 2020
Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.Meijing Liu, Xuelin Wang, Zheng Li
Pageof 1